 | Up a level |
Journal Article
Cosgarea, I, Zimmer, L., Weide, B., Gutzmer, R., Heinzerling, L., Weishaupt, C., Pfoehler, C., Gesierich, A., Herbst, R., Kaehler, K., Schlaak, M., Loquai, C., Utikal, J., Kaatz, M., Berking, C., Kreuter, A., Ulrich, J., Mohr, P., Dippel, E., Livingstone, E., Weichenthal, M., Schadendorf, D. and Ugurel, S. (2017). Interleukin-2 and Checkpoint Inhibition as a successful Therapy Sequence for metastatic Melanoma: Case Report and retrospective Analysis in 52 Patients. J. Dtsch. Dermatol. Ges., 15. S. 16 - 18. HOBOKEN: WILEY. ISSN 1610-0387
Stranzenbach, R., Dippel, E., Schlaak, M. and Stadler, R. (2018). Alternate dosing regimens of brentuximab vedotin for CD30+cutaneous T-cell lymphoma: reply from the authors. Br. J. Dermatol., 178 (1). S. 303 - 304. HOBOKEN: WILEY. ISSN 1365-2133
Stranzenbach, R., Dippel, E., Schlaak, M. and Stadler, R. (2017). Brentuximab vedotin in CD30(+) cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature. Br. J. Dermatol., 177 (6). S. 1503 - 1510. HOBOKEN: WILEY. ISSN 1365-2133